IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases
Synopsis
The company said that the data provide a strong rationale for further development of the drug in Hidradenitis Suppurative and Chronic Spontaneous Urticaria.
InflaRx N.V. (IFRX) announced on Monday that data from a mid-stage trial of its INF904 in certain skin conditions demonstrated positive outcomes, including a reduction in disease severity and pain, which sent shares rallying 80% in the pre-market session.
The company studied the experimental drug in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU). It was aimed at evaluating the safety and pharmacokinetics / pharmacodynamics profile of INF904.
While Hidradenitis suppurativa (HS) is a chronic skin disease that causes painful, boil-like lumps to form under the skin, Chronic spontaneous urticaria (CSU) is a skin condition characterized by recurrent, itchy hives (wheals) and/or swelling (angioedema) that lasts for six weeks or longer.
The company said that the data provide a strong rationale for further development of the drug in both these diseases.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.